for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Puretech Health PLC

PRTC.L

現在値

381.50GBp

変化

--(--)

本日のレンジ

--

 - 

--

52週レンジ

198.50

 - 

447.66

∙ 約20分前の相場を表示しています。

適時開示

PureTech Health Appoints George Farmer As CFO

Jan 5 (Reuters) - PureTech Health PLC <PRTC.L>::APPOINTMENT OF GEORGE FARMER, PH.D., AS CHIEF FINANCIAL OFFICER.

Puretech Health Starts LYT-200 Clinical Trial In Solid Tumors

Dec 11 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - PRTC STARTS LYT-200 CLINICAL TRIAL IN SOLID TUMORS.PURETECH HEALTH - TRIAL WILL ASSESS SAFETY AND TOLERABILITY OF ESCALATING DOSES OF LYT-200 WITH RESULTS EXPECTED IN Q4 2021.

PureTech Initiates Phase 2a trial of LYT-100 in Lymphedema

Dec 10 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH - PURETECH INITIATES PHASE 2A TRIAL OF LYT-100 (DEUPIRFENIDONE) IN LYMPHEDEMA.PURETECH HEALTH - STUDY WILL FURTHER EVALUATE SAFETY AND TOLERABILITY OF LYT-100.PURETECH HEALTH - STUDY WILL EXPLORE CLINICAL EFFICACY ENDPOINTS IN PATIENTS WITH BREAST-CANCER RELATED, UPPER LIMB SECONDARY LYMPHEDEMA.PURETECH HEALTH - SEPARATE PHASE 2 STUDY EVALUATING LYT-100 IN LONG COVID RESPIRATORY COMPLICATIONS AND RELATED SEQUELAE WAS RECENTLY INITIATED.PURETECH HEALTH - REGISTRATION-ENABLING STUDIES ARE ALSO BEING PLANNED FOR LYT-100 IN IDIOPATHIC PULMONARY FIBROSIS (IPF).PURETECH HEALTH - RESULTS FROM THIS PROOF-OF-CONCEPT STUDY ARE EXPECTED IN Q4 OF 2021.

Puretech Health Says Guidance For Exchanging Ordinary Shares Into ADSS

Nov 13 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - GUIDANCE FOR EXCHANGING ORDINARY SHARES INTO ADSS.PURETECH HEALTH- NASDAQ HAS APPROVED ADSS FOR LISTING, & ADSS ARE EXPECTED BEGIN TRADING ON NASDAQ GLOBAL MARKET UNDER SYMBOL "PRTC" ON 16 NOV 2020.

Puretech Health Start Nasdaq Trading On Nov. 16

Nov 13 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - PURETECH TO COMMENCE NASDAQ TRADING ON 16 NOVEMBER.PURETECH HEALTH - EXPECTS TRADING OF AMERICAN DEPOSITORY SHARES OF COMPANY ON NASDAQ GLOBAL MARKET WILL COMMENCE ON MONDAY, 16 NOVEMBER 2020.

Puretech Health Says Vedanta Biosciences Awarded By BARDA Up to $76.9 Mln to Advance VE303

Sept 30 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH - FOUNDED ENTITY VEDANTA BIOSCIENCES AWARDED UP TO $76.9 MILLION INCLUDING $7.4 MILLION UPFRONT FROM BARDA TO ADVANCE DEVELOPMENT OF VE303.

Puretech Health Says Sonde Makes Acquisition In Vocal Biomarker Space

Aug 25 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - SONDE MAKES ACQUISITION IN VOCAL BIOMARKER SPACE.PURETECH HEALTH SAYS ITS FOUNDED ENTITY, SONDE HEALTH, HAS ACQUIRED NEUROLEX LABORATORIES, INC.PURETECH HEALTH- JIM SCHWOEBEL, CHIEF EXECUTIVE OFFICER OF NEUROLEX, WILL JOIN SONDE'S LEADERSHIP TEAM AS VICE PRESIDENT.PURETECH HEALTH - TRANSACTION DID NOT INVOLVE ANY FINANCIAL PARTICIPATION FROM PURETECH.

Puretech Health Says Akili Received European Approval to Market EndeavorRx

June 23 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH - AKILI RECEIVED A CONFORMITÉ EUROPÉENNE (CE) MARK FOR ENDEAVORRX (AKL-T01).

Puretech Health Sells 555,500 Shares Of Karuna Therapeutics For About $45 Mln

May 26 (Reuters) - Karuna Therapeutics Inc <KRTX.O>::PURETECH HEALTH - SOLD 555,500 SHARES OF ITS FOUNDED ENTITY KARUNA THERAPEUTICS FOR ABOUT $45 MILLION.

Puretech Health Says Clinical Trial Initiated Of Wholly-Owned Candidate

March 3 (Reuters) - PureTech Health PLC <PRTC.L>::PURETECH HEALTH PLC - CLINICAL TRIAL INITIATED OF WHOLLY-OWNED CANDIDATE.PURETECH HEALTH PLC - FIRST PARTICIPANT DOSED IN CLINICAL TRIAL OF WHOLLY-OWNED LYMPHOEDEMA CANDIDATE LYT-100.PURETECH HEALTH - MANY ASCENDING DOSE, FOOD EFFECT STUDY WILL BE FOLLOW-UP TO PREVIOUSLY CONDUCTED SINGLE ASCENDING DOSE CLINICAL TRIAL OF LYT-100.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up